Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Corcept Therapeutics (CORT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,532,323
  • Shares Outstanding, K 114,120
  • Annual Sales, $ 81,320 K
  • Annual Income, $ 8,140 K
  • 36-Month Beta 1.89
  • Price/Sales 22.23
  • Price/Cash Flow 287.15
  • Price/Book 28.00

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.30 +54.12%
on 12/19/17
23.77 -0.80%
on 01/18/18
+7.03 (+42.48%)
since 12/18/17
3-Month
15.30 +54.12%
on 12/19/17
23.77 -0.80%
on 01/18/18
+5.11 (+27.67%)
since 10/18/17
52-Week
6.70 +251.94%
on 01/31/17
23.77 -0.80%
on 01/18/18
+15.86 (+205.44%)
since 01/18/17

Most Recent Stories

More News
Trevena Announces FDA Acceptance of Olinvo NDA, Shares Up

FDA accepts Trevena's (TRVN) NDA for acute pain drug, Olinvo.

TRVN : 1.73 (unch)
CORT : 23.58 (+6.26%)
ACRX : 2.03 (-1.22%)
MNK : 21.70 (-2.60%)
Achaogen's NDA for Plazomicin Gets Priority Review From FDA

Achaogen's (AKAO) NDA for its urinary tract infections candidate, plazomicin, gets FDA's priority review.

CORT : 23.58 (+6.26%)
PTX : 2.51 (+1.62%)
AKAO : 11.59 (-2.03%)
PFE : 36.99 (-0.51%)
5 Reasons to Invest in Novo Nordisk (NVO) Stock Right Now

Let's take a look at few factors that help in determining if Novo Nordisk (NVO) will be a good investment in 2018.

CORT : 23.58 (+6.26%)
SCMP : 17.95 (-0.28%)
NVO : 56.51 (+0.18%)
GSK : 38.17 (+0.05%)
First Week of CORT January 19th Options Trading

Investors in Corcept Therapeutics Inc saw new options begin trading this week, for the January 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CORT options...

CORT : 23.58 (+6.26%)
TherapeuticsMD Submits NDA for VMS Candidate, Shares Rise

TherapeuticsMD (TXMD) announces submission of NDA to the FDA seeking approval of TX-001HR to treat vasomotor symptoms in post-menopausal women.

CORT : 23.58 (+6.26%)
CLDX : 2.74 (-0.72%)
ACAD : 27.78 (-1.66%)
TXMD : 6.17 (-0.32%)
What Drives Catalyst Pharmaceuticals Above 250% This Year?

We take a look at the factors that drive phenomenal growth in Catalyst Pharmaceuticals' (CPRX) share price in 2017.

CORT : 23.58 (+6.26%)
SCMP : 17.95 (-0.28%)
BMRN : 89.78 (+0.16%)
CPRX : 3.79 (-0.79%)
Actinium Posts Positive DMC View on Lomab-B Phase III Trial

Independent Data Monitoring Committee endorses evaluation of Actinium's (ATNM) lead pipeline candidate, Iomab-B, for a pivotal phase III SIERRA study.

CORT : 23.58 (+6.26%)
ACHN : 2.95 (+1.72%)
ACRX : 2.03 (-1.22%)
ATNM : 0.71 (-2.05%)
Horizon Pharma Gets FDA Nod for Procysbi Label Expansion

The FDA approves label expansion for Horizon Pharma's (HZNP) Procysbi (cysteamine bitartrate) delayed-release capsules for children aged a year and older with nephropathic cystinosis.

CORT : 23.58 (+6.26%)
SCMP : 17.95 (-0.28%)
ACHN : 2.95 (+1.72%)
HZNP : 15.21 (+1.47%)
Insys' Cannabidiol Gets Fast Track Designation in the U.S.

The FDA grants a fast track status to Insys' (INSY) cannabidiol oral solution for Prader-Willi syndrome. The company also plans to move the candidate into clinical development in first-quarter 2018.

CORT : 23.58 (+6.26%)
ACHN : 2.95 (+1.72%)
GWPH : 131.99 (-0.34%)
INSY : 8.53 (-5.12%)
Agios (AGIO) Files NDA for Leukemia Candidate in the U.S.

Agios (AGIO) submits new drug application to the FDA for ivosidenib for relapsed or refractory acute myeloid leukemia and IDH1 mutation. The company has also filed request for a priority review.

CORT : 23.58 (+6.26%)
AGIO : 68.15 (-3.10%)
CELG : 101.72 (-0.29%)
ACHN : 2.95 (+1.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy and ranks in the Top 1% of all short term signal directions.

Longer term, the trend strength is Maximum. Long term indicators mostly agree with the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

Corcept Therapeutics Incorporated is a pharmaceutical company. It is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The company focuses on disorders that are associated with a steroid hormone called cortisol....

See More

Key Turning Points

2nd Resistance Point 24.94
1st Resistance Point 24.26
Last Price 23.58
1st Support Level 22.41
2nd Support Level 21.24

See More

52-Week High 23.77
Last Price 23.58
Fibonacci 61.8% 17.25
Fibonacci 50% 15.24
Fibonacci 38.2% 13.22
52-Week Low 6.70

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.